Masimo Corporation (NASDAQ: MASI) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 123.25 | EPS (ttm) | 1.46 | Insider Own | 11.50% | Shs Outstand | 52.37M | Perf Week | 0.63% |
| Market Cap | 9.42B | Forward P/E | 26.79 | EPS next Y | 6.72 | Insider Trans | 0.00% | Shs Float | 44.31M | Perf Month | 0.86% |
| Enterprise Value | 9.78B | PEG | 16.61 | EPS next Q | - | Inst Own | - | Short Float | - | Perf Quarter | 2.54% |
| Income | 76.00M | P/S | 6.04 | EPS this Y | 310.62% | Inst Trans | - | Short Ratio | - | Perf Half Y | 28.75% |
| Sales | 1.56B | P/B | 11.94 | EPS next Y | 12.05% | ROA | 4.64% | Short Interest | - | Perf YTD | 38.36% |
| Book/sh | 15.07 | P/C | 75.39 | EPS next 5Y | 7.42% | ROE | 9.08% | 52W High | 179.99 -0.02% | Perf Year | 7.75% |
| Cash/sh | 2.39 | P/FCF | 45.13 | EPS past 3/5Y | - | ROIC | 18.28% | 52W Low | 125.94 42.89% | Perf 3Y | 9.61% |
| Dividend Est. | - | EV/EBITDA | 28.34 | Sales past 3/5Y | -9.14% 5.95% | Gross Margin | 61.73% | Volatility | 0.01% 0.13% | Perf 5Y | -13.94% |
| Dividend TTM | - | EV/Sales | 6.27 | EPS Y/Y TTM | 125.52% | Oper. Margin | 19.85% | ATR (14) | 0.31 | Perf 10Y | 260.33% |
| Dividend Ex-Date | Nov 23, 2012 | Quick Ratio | 1.45 | Sales Y/Y TTM | -25.50% | Profit Margin | 4.90% | RSI (14) | 74.86 | Recom | 2.39 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.68 | EPS Q/Q | 5.15% | SMA20 | 0.52% | Beta | 1.07 | Target Price | 180.00 |
| Payout | 0.00% | Debt/Eq | 0.76 | Sales Q/Q | 8.60% | SMA50 | 0.71% | Rel Volume | 0.00 | Prev Close | 179.95 |
| Employees | 7,500 | LT Debt/Eq | 0.76 | Earnings | Aug 04 | SMA200 | 15.05% | Avg Volume | 1.03M | Price | 179.95 |
| IPO Date | Aug 08, 2007 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -0.14% 0.21% | Net Debt/EBITDA | 1.05 | Volume | 0 | Change | 0.00% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Mar-27-26 | Downgrade | Raymond James | Outperform → Market Perform | |
| Feb-18-26 | Downgrade | Wells Fargo | Overweight → Equal Weight | |
| Feb-18-26 | Downgrade | BTIG | Buy → Neutral | |
| Feb-17-26 | Reiterated | Stifel Nicolaus | Buy | $170 → $180 |
| Feb-17-26 | Reiterated | Piper Sandler | Overweight | $210 → $180 |
| Dec-05-25 | Reiterated | Wells Fargo | Overweight | $187 → $190 |
| Dec-04-25 | Reiterated | BTIG | Buy | $193 → $200 |
| May-07-25 | Reiterated | BTIG | Buy | $206 → $193 |
| Dec-18-24 | Reiterated | Piper Sandler | Overweight | $165 → $210 |
| Nov-06-24 | Upgrade | Raymond James | Market Perform → Outperform | $170 |
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Iris, iSirona, Replica, and UniView; and brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 1/3/2026 | FY 2024 12/28/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,560 | 1,527 | 2,094 | 2,048 | 2,036 | 1,239 | 1,144 | 938 | 858 | |
| Cost of Goods Sold Incl. D&A | 597 | 582 | 1,090 | 1,045 | 977 | 431 | 401 | 309 | 283 | |
| Gross Profit | 962 | 945 | 1,004 | 1,004 | 1,059 | 808 | 743 | 629 | 575 | |
| Selling, General and Administrative Excl. Other | 529 | 506 | 744 | 664 | 657 | 395 | 369 | 315 | 285 | |
| Research and Development | 123 | 126 | 223 | 175 | 191 | 137 | 119 | 93 | 81 | |
| Other Operating Expense | 0 | 0 | 304 | 28 | 1 | 1 | -1 | 0 | 1 | |
| Operating Income | 310 | 313 | -267 | 137 | 210 | 276 | 256 | 221 | 208 | |
| Interest Expense | 31 | 33 | 44 | 50 | 26 | 0 | 0 | 0 | 1 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -3 | -7 | 5 | 2 | 9 | -1 | 8 | 13 | 6 | |
| Net Income Before Taxes | 275 | 273 | -305 | 88 | 193 | 274 | 264 | 234 | 214 | |
| Income Taxes | 59 | 65 | 0 | 7 | 50 | 45 | 23 | 38 | 20 | |
| Consolidated Net Income | 76 | -151 | -305 | 82 | 144 | 230 | 240 | 196 | 194 | |
| Net Income From Continuing Operations | 217 | 208 | -305 | 82 | 144 | 230 | 240 | 196 | 194 | |
| Net Income | 76 | -151 | -305 | 82 | 144 | 230 | 240 | 196 | 194 | |
| EPS (Recurring) | 1.44 | -2.83 | -5.72 | 1.54 | 2.68 | 4.16 | 4.39 | 3.67 | 3.45 | |
| EPS (Basic, Before Extraordinaries) | 1.44 | -2.83 | -5.72 | 1.54 | 2.68 | 4.16 | 4.39 | 3.67 | 3.45 | |
| EPS (Diluted) | 1.46 | -2.80 | -5.72 | 1.51 | 2.60 | 3.98 | 4.14 | 3.44 | 3.45 | |
| EBITDA | 345 | 345 | -159 | 237 | 355 | 310 | 293 | 258 | 236 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 123.25 | — | — | 77.62 | 56.90 | 73.56 | 64.83 | 45.95 | 31.12 | |
| Price To Sales Ratio | 6.00 | 4.51 | 4.33 | 3.03 | 3.92 | 13.00 | 12.90 | 8.93 | 7.01 | |
| Gross Margin | 61.67 | 61.89 | 47.95 | 49.02 | 52.01 | 65.21 | 64.95 | 67.06 | 67.02 | |
| Operating Margin | 19.87 | 20.50 | -12.75 | 6.69 | 10.31 | 22.28 | 22.38 | 23.56 | 24.24 | |
| Net Margin | 4.87 | -9.89 | -14.57 | 4.00 | 7.07 | 18.56 | 20.98 | 20.90 | 22.61 | |
| Shares Outstanding | 52 | 54 | 53 | 53 | 54 | 55 | 55 | 53 | 56 | |
| Market Capitalization | 9,357 | 6,880 | 9,061 | 6,212 | 7,989 | 16,103 | 14,761 | 8,377 | 6,013 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Scannell Timothy J | Director | Apr 29 '26 | Option Exercise | 0.00 | 1,225 | 0 | 2,608 | May 05 |
| LANE WENDY E | Director | Apr 29 '26 | Option Exercise | 0.00 | 1,225 | 0 | 2,608 | May 05 |
| Brennan Michelle | director, other: Chairman of the Board | Apr 29 '26 | Option Exercise | 0.00 | 1,225 | 0 | 8,543 | May 05 |
| Hellmann Elisabeth A | Chief Human Resources Officer | Apr 21 '26 | Option Exercise | 0.00 | 335 | 0 | 335 | May 05 |
| Szyman Catherine M. | CEO | Mar 11 '26 | Option Exercise | 0.00 | 2,101 | 0 | 8,674 | Mar 16 |
| Young Micah W | EVP & Chief Financial Officer | Mar 11 '26 | Option Exercise | 0.00 | 873 | 0 | 26,127 | Mar 16 |
| Young Micah W | EVP & Chief Financial Officer | Feb 27 '26 | Option Exercise | 0.00 | 15,000 | 0 | 0 | Mar 03 |
| Szyman Catherine M. | CEO | Feb 12 '26 | Option Exercise | 132.96 | 11,141 | 1,481,307 | 11,141 | Feb 13 |
| Sampath Anand | EVP, Ops & Clinical Research | Jan 28 '26 | Option Exercise | 37.84 | 30,000 | 1,135,200 | 59,589 | Jan 30 |
| Sampath Anand | EVP, Ops & Clinical Research | Jan 28 '26 | Sale | 136.81 | 18,680 | 2,555,570 | 40,909 | Jan 30 |
| Ahmed Omar | CTIO & EVP of Engineering | Nov 13 '25 | Option Exercise | 152.43 | 2,474 | 377,112 | 4,242 | Nov 17 |
| Tripodi Blair | COO, Consumer Division | Sep 23 '25 | Option Exercise | 142.13 | 15,000 | 2,131,950 | 21,896 | Sep 25 |
| Brennan Michelle | director, other: Chairman of the Board | Aug 13 '25 | Buy | 155.25 | 100 | 15,525 | 7,318 | Aug 14 |
| Brennan Michelle | director, other: Chairman of the Board | Aug 12 '25 | Buy | 150.35 | 100 | 15,035 | 7,218 | Aug 14 |
| Jellison William R | Director | Aug 11 '25 | Buy | 145.98 | 3,000 | 437,940 | 4,790 | Aug 12 |